Clinical Trial

Self-Expanding Coronary Sinus Reducer for Treatment of Symptomatic Coronary Microvascular Dysfunction (CMD) (SERRA-I Study)

Recruiting
View on ClinicalTrials.gov →
Summary
VahatiCor's Coronary Sinus Reducer (A-FLUX) has been designed to improve angina or angina-like symptoms in patients with CMD. SERRA-I is an early feasibility study that evaluates the safety and clinical performance of the A-FLUX Reducer in this population.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-05-19; most recent amendment 2026-05-14.
Status change: Not Yet Recruiting → Recruiting 2025-08-20
Trial Details
NCT Number NCT06991322
Lead Sponsor VahatiCor, Inc.
Conditions Coronary Microvascular Dysfunction, Coronary Microvascular Disease
Enrollment 30 participants
Start Date 2025-06-18
Primary Completion 2026-12 (estimated)
Study Completion 2027-04 (estimated)
Updated on ClinicalTrials.gov 2026-05-15